Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients

被引：0
|
作者：
Nishimura, Meiko
Kogawa, Takahiro
Akaishi, Yuko
Ogata, Misato
Masuda, Jun
Terada, Mitsuo
Sakai, Hitomi
Nozawa, Kazuki
Kurozumi, Sasagu
Yokoe, Takamichi
Ozaki, Yukinori Ozaki
Yazaki, Shu
Onishi, Mai
Iwasa, Tsutomu
Onoe, Takuma
Okumura, Yuta
Nakayama, Sayaka
Hagio, Kanako
Takahashi, Yuko
Tanino, Hirokazu
Tsurutani, Junji
Matsumoto, Koji
Shimokawa, Mototsugu
Takano, Toshimi
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-19-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-19-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Sakurada, Akihisa
    Kinoshita, Tetsuhiko
    Shimizu, Ken
    ANTICANCER RESEARCH, 2022, 42 (02) : 1099 - 1106
  • [2] Efficacy of subsequent-abemaciclib treatment after disease progression on palbociclib combined with endocrine therapy in patients with ER-positive HER2-negative metastatic breast cancer
    Seki, Hirohito
    Nakai, Taketo
    Shimizu, Ken
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [4] Liquid Biopsy Testing in a Greek Cohort of ER-positive, HER2-negative metastatic breast cancer patients
    Tsoulos, Nikolaos
    Meintani, Angeliki
    Kapetsis, Georgios
    Chatzigiannidou-Florou, Chrysiis
    Tsantikidi, Aikaterini
    Maxouri, Stella
    Thanou, Eleni
    Aggelaina, Kalliopi
    Metaxa-Mariatou, Vasiliki
    Tsaousis, Georgios
    Natsiopoulos, Ioannis
    Venizelos, Vasileios
    Markopoulos, Christos
    Zagouri, Flora
    Kampletsas, Eleftherios
    Karyda, Eirini
    Tryfonopoulos, Dimitrios
    Papazisis, Konstantinos
    Ziogas, Dimitrios
    Athanasiadis, Ilias
    Papadopoulou, Eirini
    Nasioulas, Georgios
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [6] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [7] Clinical implications of molecular heterogeneity in highly proliferative, ER-positive, HER2-negative breast cancer
    Bianchini, G.
    Pusztai, L.
    Kelly, C. M.
    Iwamoto, T.
    Callari, M.
    Symmans, W. F.
    Gianni, L.
    CANCER RESEARCH, 2012, 72
  • [8] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [9] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 17 - 17
  • [10] A Multicenter, Phase Ib/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
    Casasanta, Nicole
    Landry, Chrystal
    Shao, Theresa
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Berger, Natalie
    Moshier, Erin
    Joshi, Gargi Atul
    Vaccaro, Rita
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2024, 84 (09)
12345